Baseline Tests Before Starting Sprycel
Patients starting dasatinib (Sprycel) for chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) need baseline assessments including complete blood count (CBC) with differential, liver function tests (ALT, AST, bilirubin), electrolytes (especially potassium, magnesium, phosphorus), renal function (creatinine), QTc interval via ECG, and echocardiogram or MUGA scan for ejection fraction.[1][2]
Routine Blood Monitoring During Treatment
CBC with differential is required weekly for the first 2 months, then biweekly for months 3 and 4, and monthly thereafter to detect cytopenias like neutropenia or thrombocytopenia, which affect up to 80% of patients.[1][2] Electrolyte panels (calcium, magnesium, phosphate, potassium) should be checked periodically due to risk of hypophosphatemia or other imbalances from the drug's effects on renal phosphate handling.[1]
Cardiac Monitoring Schedule
ECG for QTc prolongation is needed at baseline, then as clinically indicated, especially with concurrent QT-prolonging drugs or electrolyte issues—Sprycel carries a risk of QT prolongation in 2-4% of patients.[1][2] Pulmonary arterial hypertension (PAH) screening involves echocardiogram at baseline and as symptoms arise (e.g., dyspnea, fatigue), with incidence around 0.5-1%.[1] Left ventricular dysfunction requires periodic echocardiograms or MUGA scans per institutional guidelines.[2]
Liver and Other Organ Checks
Liver enzymes (ALT, AST) are monitored monthly initially, then every 1-3 months, as elevations occur in 20-40% of patients, sometimes leading to discontinuation.[1][2] Renal function and urinalysis help track any proteinuria or fluid retention linked to pleural effusions (seen in 15-20% of cases).[1]
Response Monitoring for CML
Beyond safety, bone marrow biopsy and cytogenetic analysis occur at 3, 6, and 12 months, then yearly, to assess BCR-ABL transcript levels via PCR for treatment response (e.g., major molecular response).[1][2] Switch monitoring if resistance emerges.
What Happens If Levels Drop or Symptoms Appear
Dose interruptions or reductions follow for grade 3-4 cytopenias (ANC <1000/μL or platelets <50,000/μL); resume at full dose once recovered.[1] Report chest pain, shortness of breath, or palpitations immediately for urgent cardiac/pulmonary evaluation.[2]
Sources
[1] Sprycel Prescribing Information (Bristol Myers Squibb)
[2] NCCN Guidelines for CML, Version 2.2024